The device was not returned for analysis.A review of the lot history record review could not be performed as the part and lot information regarding the complaint device was not provided.Based on the information reviewed, a cause for the reported tissue damage cannot be determined.The reported mitral regurgitation resulted in dyspnea, atrial fibrillation and heart failure; however, are related to the tissue damage.Tissue damage, dyspnea, atrial fibrillation, heart failure and mitral regurgitation are listed in the instructions for use (ifu) as known possible complications associated with mitraclip procedures.The additional therapy/non-surgical treatment and hospitalization were a result of case-specific circumstances.There is no indication of a product issue with respect to manufacture, design or labeling.
|
This is filed to report post mitraclip procedure, tissue damage, atrial fibrillation, heart failure and recurrent mitral regurgitation occurred.It was reported that the initial mitraclip procedure was performed in (b)(6) 2017 to treat degenerative mitral regurgitation (mr) with a grade of 4+.Two clips were implanted, reducing the mr to 2.On (b)(6) 2021, the patient presented with dyspnea, atrial fibrillation and heart failure.A control echocardiogram was performed, found the clips stable with no evidence of a single leaflet device attachment but there was a chordae rupture on the p2 leaflet and residual mr at the rupture level.On (b)(6) 2021, an additional clip was implanted lateral to the previous 2 clip implants, reducing mr from 4 to 1.The procedure was successful.No additional information was provided.
|